DRREDDY

Dr. Reddy's Laboratories Limited · NSE · INE089A01031 · F&O · lot 625 · 272 sessions on record

₹1,206.20▼ −26.80 · −2.2%from ₹1,233.00 the session before · 1 Oct 2026 close · NSE end of day

Open: ₹1,233.00
High: ₹1,233.90
Low: ₹1,194.90
Day's range: ₹393.2% of the previous close
VWAP: ₹1,212.16close −0.49% from it
Volume, shares: 26 L1.42× the 20-session average
Turnover, ₹ crore: 320
Trades: 1.1 L23 shares per trade
Previous close: ₹1,233.00−26.80 to the close
Price band, next session: ₹1,085.60 – ₹1,326.8010% either side of the close · dynamic, widened in 5% steps when hit

Day range29% of the way up

₹1,194.90₹1,233.90

52-week range34% of the way up

₹1,101.00 23 Jul₹1,414.90 29 Jun

−15% from the high · +9.6% from the low

The desk read · 1 Octexpiry 27 Oct · 26 days

long unwinding

futures read

price −2.2% · OI −2.0%

+4.50

futures premium, ₹

+0.4% to spot ₹1,206.20

0.76

puts per call, by OI

by volume 0.95

1,200

max pain

−0.51% from the close

▼ −2.0%

futures OI on the day

−640 lots · 32,000 open

Long unwinding into a 26-day expiry: futures OI −2.0% on a −2.2% day, the most call OI sits at 1,200, the most put OI at 1,200, max pain 1,200.

Futures and options

1 Oct close · lot 625 · NSE end of day

DRREDDY futures closed at ₹1,210.70, +0.4% to spot, with 99% of open interest in the 27 Oct contract, and the 1,210 straddle prices a move of about ±5.5% by expiry.

Futures by expiryall 3 contracts NSE lists on the stock · basis against the spot close ₹1,206.20

Futures by expiry, basis against the spot close ₹1,206.20
Expiry	Close ₹	Basis ₹ · %	Annualised %	OI lots · on the day	Share of OI %	Contracts traded
27 Oct26 days	₹1,210.70	+4.50+0.4%	+5.2%	31,000▼ −2.1% · −660 lots	99	3,000
23 Nov53 days	₹1,209.00	+2.80+0.2%	+1.6%	360▲ +2.9% · +10 lots	1.1	89
29 Dec89 days	₹1,205.00	−1.20−0.1%	−0.41%	14▲ +100.0% · +7.0 lots	0.04	8.0

1.2% of futures OI sits beyond the 27 Oct contract · 54 of 75 listed contracts traded · 19,000 option contracts changed hands

Options27 Oct expiry · 26 days

The 1,210 straddle closed at ₹66.05 (call 33.40 + put 32.65), pricing a move of about ±5.5% by the 27 Oct expiry. In the last 253 windows of 19 sessions, DRREDDY moved more than that 73 times.

Call OI, lots: 8,70054 L shares
Put OI, lots: 6,60041 L shares
Puts per call, by OI: 0.76by volume 0.95
Max pain: 1,200−0.51% from the close
Contracts traded: 54 of 75listed for this expiry

Open interest by strike, lotstop three strikes each side

Calls

Strike

Puts

800

1,380

790

1,250

1,220

480

1,700

1,200

1,600

1,100

1,200

Open interest added on the day, lotsthree largest additions each side

Calls

Strike

Puts

+690

1,380

+120

1,340

+160

1,300

1,140

+61

1,130

+170

1,100

+690

Close ₹ · Nifty 50 rebased to the first close · futures open interest by the day's build-up126 sessions to 1 Oct · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it

272 sessions on file · from 28 Aug

DRREDDY close
Nifty 50, rebased
long build-up · price up, OI up
short build-up · price down, OI up
short covering · price up, OI down
long unwinding · price down, OI down

Session read · latest close: 1 Oct 2026
Close ₹ · day %: ₹1,206.20▼ −2.2% on the previous close
Against Nifty 50: Nifty −0.9%−1.3 pp difference on the day
Futures OI, lots: 32,000−640 lots · −2.0% on the day
The day's build-up: long unwindingprice −2.2% · OI −2.0%
Against the averages: above 20 · above 5020-session ₹1,181.69 (+2.1%) · 50-session ₹1,176.25 (+2.5%)
Volume: 1.42×the previous 20 sessions · 26 L shares
Extremes on the day: none

The market after the news

close against the last close before each bulletin · Nifty 50 over the same sessions

After the last 8 bulletins, DRREDDY closed higher five sessions later in 3 of 6.

Close after each bulletin on the day, one session later and five sessions later, with Nifty 50 and futures open interest
Bulletin	Day of the news	1 session later	5 sessions later	Futures OI on the day
29 SeptNifty 50 declines as bond yields rise and risks escalate	▲ +2.5%Nifty −0.3% · +2.8 pp	▲ +1.0%Nifty −0.7% · +1.7 pp	—not reached	▲ +1.4%long build-up
25 SeptDr. Reddy's faces fraud probe after Q1 earnings drop	▲ +0.1%Nifty +0.3% · −0.3 pp	▲ +1.7%Nifty −1.2% · +3.0 pp	—not reached	▲ +3.1%long build-up
21 SeptSensex, Nifty open lower amid crude oil price rise	▲ +1.1%Nifty +0.3% · +0.8 pp	▲ +2.2%Nifty −0.1% · +2.3 pp	▲ +3.0%Nifty −2.4% · +5.5 pp	▲ +0.2%long build-up
20 SeptSensex, Nifty open lower amid geopolitical tensions	▲ +1.1%Nifty +0.3% · +0.8 pp	▲ +2.2%Nifty −0.1% · +2.3 pp	▲ +3.0%Nifty −2.4% · +5.5 pp	▲ +0.2%long build-up
17 SeptDr Reddy's Q1FY27 results show revenue decline and margin pressures	▲ +0.8%Nifty +0.3% · +0.5 pp	▲ +2.0%Nifty +0.6% · +1.4 pp	▲ +2.2%Nifty −0.6% · +2.8 pp	▲ +1.8%long build-up
24 JulSensex, Nifty open lower on crude oil price rise	▼ −1.3%Nifty −0.4% · −0.8 pp	▼ −1.3%Nifty +0.5% · −1.9 pp	▼ −1.6%Nifty +2.1% · −3.7 pp	▲ +6.7%short build-up
23 JulUS House approves $95 billion Iran war funding; Dr Reddy’s declines	▼ −1.3%Nifty −0.4% · −0.8 pp	▼ −1.3%Nifty +0.5% · −1.9 pp	▼ −1.6%Nifty +2.1% · −3.7 pp	▲ +6.7%short build-up
23 JulSensex, Nifty open lower amid crude oil price rise	▼ −1.3%Nifty −0.4% · −0.8 pp	▼ −1.3%Nifty +0.5% · −1.9 pp	▼ −1.6%Nifty +2.1% · −3.7 pp	▲ +6.7%short build-up

8 of 16 bulletins

Quarterly results

consolidated · latest filed 22 Jul, 06:46 pm IST · NSE filings

Revenue ₹8,100 cr, −5.5% on a year earlier; profit ₹436 cr, −69% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidated₹ crore as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, Nifty 50 over the same session

Quarterly results of DRREDDY on the consolidated basis with the market's move on the first session after each filing
Quarter	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹	Market on the day
Jun 2026filed 22 Jul	₹8,100 cr	▼ −5.5%	₹436 cr	▼ −69%	5.33	▼ −1.4%Nifty −0.5% · −0.9 pp
Mar 2026filed 12 May · audited	₹7,546 cr	▼ −12%	₹221 cr	▼ −86%	2.65	▼ −0.4%Nifty +0.1% · −0.5 pp
Dec 2025filed 21 Jan	₹8,753 cr	▲ +4.4%	₹1,190 cr	▼ −15%	14.52	▲ +5.2%Nifty +0.5% · +4.7 pp
Sept 2025filed 24 Oct	₹8,828 cr	▲ +9.8%	₹1,337 cr	▼ −0.38%	16.17	▲ +0.1%Nifty +0.7% · −0.6 pp
Jun 2025filed 23 Jul	₹8,572 cr	▲ +11%	₹1,410 cr	▲ +1.3%	17.02	▲ +1.4%Nifty −0.6% · +2.1 pp
Mar 2025filed 9 May · audited	₹8,528 cr	▲ +20%	₹1,587 cr	▲ +21%	19.10	▲ +3.4%Nifty +3.8% · −0.4 pp
Dec 2024filed 24 Jan	₹8,381 cr	▲ +16%	₹1,404 cr	▲ +1.7%	16.94	▼ −5.0%Nifty −0.5% · −4.5 pp
Sept 2024filed 5 Nov	₹8,038 cr	▲ +16%	₹1,342 cr	▼ −9.5%	15.05	▲ +2.4%Nifty +1.1% · +1.2 pp

By financial yearApril to March · each year the sum of its four quarters as filed, consolidated · EPS summed across the quarters · only complete years

Financial-year results of DRREDDY on the consolidated basis, summed from the quarters filed
Year	Revenue ₹ cr	Revenue YoY	Profit ₹ cr	Profit YoY	EPS ₹
FY26to Mar 2026	₹33,700 cr	▲ +3.2%	₹4,158 cr	▼ −27%	50.36
FY25to Mar 2025	₹32,644 cr	▲ +17%	₹5,725 cr	▲ +2.6%	134.57
FY24to Mar 2024	₹28,011 cr	—	₹5,578 cr	—	334.61

Fundamentals

consolidated · filings to Jun 2026 · close ₹1,206.20 on 1 Oct

DRREDDY trades at 31 times trailing earnings against 38 for its industry, 2.6 times book value, revenue −0.87% over twelve months, a 1.3% dividend yield, market cap ₹1,00,000 cr.

Valuationarithmetic on filings and the close · each cell names what it rests on · — where an input is missing

Market cap: ₹1,00,000 cron 1 Oct · free float ₹74,000 cr
Price to earnings: 31consolidated · four quarters to Jun 2026 · industry 38
Trailing EPS: ₹38.67diluted · consolidated · four quarters to Jun 2026
Price to book: 2.6consolidated · balance sheet to Mar 2026
Book value a share: ₹458.03consolidated · balance sheet to Mar 2026 · over NSE's share count
Debt to equity: 0.16borrowings over equity · consolidated · balance sheet to Mar 2026
Return on equity: 8.8%trailing profit over average equity · consolidated
Dividend yield: 1.3%₹16.00 a share in 365 days
Face value: ₹1a share
Shares outstanding: 83 cron 1 Oct

Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated

Revenue, trailing 12 months: ₹33,228 crfour quarters to Jun 2026
Revenue growth, 12 months: ▼ −0.87%against the twelve months before
Revenue 2-year CAGR: ▲ +7.1%trailing twelve months against the twelve months 2 years earlier · consolidated
Profit, trailing 12 months: ₹3,183 crfour quarters to Jun 2026
Profit growth, 12 months: ▼ −45%against the twelve months before
Profit 2-year CAGR: ▼ −24%trailing twelve months against the twelve months 2 years earlier · consolidated

PeersBSE sub-group Pharmaceuticals · F&O stocks with filings on record · industry P/E 38, market caps over trailing profit of 13 stocks

Stocks in the BSE sub-group Pharmaceuticals with market cap, price to earnings and price to book
Stock	Market cap ₹	P/E	P/B	Close ₹
SUNPHARMASun Pharmaceutical Industries Limited	4,30,000 cron 1 Oct	36consolidated	5.2	₹1,801.00
DIVISLABDivi's Laboratories Limited	2,50,000 cron 1 Oct	52consolidated	15	₹9,249.00
TORNTPHARMTorrent Pharmaceuticals Limited	1,80,000 cron 1 Oct	76consolidated	10	₹4,767.30
ZYDUSLIFEZydus Lifesciences Limited	1,10,000 cron 1 Oct	26consolidated	3.9	₹1,145.70
CIPLACipla Limited	1,10,000 cron 1 Oct	32consolidated	3.1	₹1,344.00
LAURUSLABSLaurus Labs Limited	1,10,000 cron 1 Oct	85consolidated	20	₹1,984.00
MANKINDMankind Pharma Limited	1,00,000 cron 1 Oct	51consolidated	6.3	₹2,535.00
DRREDDYDr. Reddy's Laboratories Limited	1,00,000 cron 1 Oct	31consolidated	2.6	₹1,206.20
AUROPHARMAAurobindo Pharma Limited	96,000 cron 1 Oct	26consolidated	2.5	₹1,676.80
LUPINLupin Limited	93,000 cron 1 Oct	17consolidated	4.1	₹2,031.20
GLENMARKGlenmark Pharmaceuticals Limited	66,000 cron 1 Oct	37consolidated	6.3	₹2,331.00
ALKEMAlkem Laboratories Limited	62,000 cron 1 Oct	29consolidated	4.3	₹5,220.00
BIOCONBiocon Limited	60,000 cron 1 Oct	110consolidated	1.6	₹370.70
ABBOTINDIAAbbott India Limited	57,000 cron 1 Oct	—	—	₹26,840.00
IPCALABIPCA Laboratories Limited	49,000 cron 1 Oct	—	5.2	₹1,943.20
GLANDGland Pharma Limited	47,000 cron 1 Oct	—	4.6	₹2,874.40
GLAXOGlaxoSmithKline Pharmaceuticals Limited	47,000 cron 1 Oct	—	21	₹2,771.10
AJANTPHARMAjanta Pharma Limited	45,000 cron 1 Oct	—	9.9	₹3,581.00
EMCUREEmcure Pharmaceuticals Limited	37,000 cron 1 Oct	—	7.4	₹1,944.60
WOCKPHARMAWockhardt Limited	34,000 cron 1 Oct	—	6.4	₹2,083.90
SAILIFESai Life Sciences Limited	33,000 cron 1 Oct	—	13	₹1,541.20
NEULANDLABNeuland Laboratories Limited	28,000 cron 1 Oct	—	15	₹21,505.00
RUBICONRubicon Research Limited	27,000 cron 1 Oct	—	21	₹1,630.90
PPLPHARMAPiramal Pharma Limited	26,000 cron 1 Oct	—	3.2	₹197.95
ACUTAASAcutaas Chemicals Limited	26,000 cron 1 Oct	—	15	₹3,196.50
SHILPAMEDShilpa Medicare Limited	21,000 cron 1 Oct	—	8.0	₹1,064.10
GRANULESGranules India Limited	20,000 cron 1 Oct	—	4.0	₹821.75
CAPLIPOINTCaplin Point Laboratories Limited	20,000 cron 1 Oct	—	5.5	₹2,631.90
PFIZERPfizer Limited	18,000 cron 1 Oct	—	4.2	₹3,858.90
ONESOURCEOnesource Specialty Pharma Limited	17,000 cron 1 Oct	—	3.0	₹1,508.00
COHANCECohance Lifesciences Limited	17,000 cron 1 Oct	—	4.3	₹451.30
ALIVUSAlivus Life Sciences Limited	17,000 cron 1 Oct	—	5.1	₹1,374.20
ERISEris Lifesciences Limited	16,000 cron 1 Oct	—	4.2	₹1,189.80
NATCOPHARMNatco Pharma Limited	16,000 cron 1 Oct	—	1.8	₹821.30
APLLTDAlembic Pharmaceuticals Limited	16,000 cron 1 Oct	—	2.8	₹815.25
JUBLPHARMAJubilant Pharmova Limited	16,000 cron 1 Oct	—	2.2	₹999.30
ASTRAZENAstraZeneca Pharma India Limited	15,000 cron 1 Oct	—	17	₹6,031.00
MARKSANSMarksans Pharma Limited	15,000 cron 1 Oct	—	4.8	₹325.60
CONCORDBIOConcord Biotech Limited	14,000 cron 1 Oct	—	7.1	₹1,374.10
AKUMSAkums Drugs and Pharmaceuticals Limited	13,000 cron 1 Oct	—	3.8	₹813.10
CORONACORONA Remedies Limited	12,000 cron 1 Oct	—	17	₹2,029.40
BLUEJETBlue Jet Healthcare Limited	10,000 cron 1 Oct	—	7.5	₹541.80
VIYASHViyash Scientific Limited	10,000 cron 1 Oct	—	3.3	₹231.75
STARStrides Pharma Science Limited	10,000 cron 1 Oct	—	3.2	₹1,084.80
PGHLProcter & Gamble Health Limited	8,900 cron 1 Oct	—	17	₹5,360.00
AARTIPHARMAarti Pharmalabs Limited	8,800 cron 1 Oct	—	4.1	₹968.50
SANOFICONRSanofi Consumer Healthcare India Limited	8,700 cron 1 Oct	—	25	₹3,787.20
SYMBIOTECSymbiotec Pharmalab Limited	7,700 cron 1 Oct	—	—	₹1,198.00
SUPRIYASupriya Lifescience Limited	7,500 cron 1 Oct	—	6.3	₹931.00
MOREPENLABMorepen Laboratories Limited	7,300 cron 1 Oct	—	5.9	₹133.70
SANOFISanofi India Limited	7,000 cron 1 Oct	—	8.5	₹3,037.40
INNOVACAPInnova Captab Limited	6,700 cron 1 Oct	—	6.1	₹1,168.00
SPARCSun Pharma Advanced Research Company Limited	6,300 cron 1 Oct	—	4.7	₹194.15
SENORESSenores Pharmaceuticals Limited	6,200 cron 1 Oct	—	6.4	₹1,349.60
IOLCPIOL Chemicals and Pharmaceuticals Limited	6,100 cron 1 Oct	—	3.4	₹209.40
ORCHPHARMAOrchid Pharma Limited	5,900 cron 1 Oct	—	4.6	₹990.00
FDCFDC Limited	5,500 cron 1 Oct	—	2.2	₹335.90
GUJTHEMGujarat Themis Biosyn Limited	5,000 cron 1 Oct	—	—	₹381.80
NOVARTINDNovartis India Limited	4,900 cron 1 Oct	—	—	₹1,965.00
RPGLIFERPG Life Sciences Limited	4,800 cron 1 Oct	—	8.0	₹2,930.70
SMSPHARMASMS Pharmaceuticals Limited	4,400 cron 1 Oct	—	5.6	₹471.30
GUFICBIOGufic Biosciences Limited	4,200 cron 1 Oct	—	6.3	₹418.40
AARTIDRUGSAarti Drugs Limited	3,800 cron 1 Oct	—	2.5	₹421.00
UNICHEMLABUnichem Laboratories Limited	3,800 cron 1 Oct	—	1.4	₹535.05
KPLKwality Pharmaceuticals Limited	3,700 cron 1 Oct	—	—	₹3,564.40
SOLARASolara Active Pharma Sciences Limited	3,400 cron 1 Oct	—	2.7	₹714.85
INDSWFTLABInd-Swift Laboratories Limited	3,400 cron 1 Oct	—	2.5	₹395.15
SHUKRAPHARShukra Pharmaceuticals Limited	2,700 cron 1 Oct	—	—	₹61.80
HIKALHikal Limited	2,700 cron 1 Oct	—	2.2	₹218.15
VENUSREMVenus Remedies Limited	2,400 cron 1 Oct	—	3.6	₹1,796.70
DCALDishman Carbogen Amcis Limited	2,400 cron 1 Oct	—	0.35	₹150.35
INDOCOIndoco Remedies Limited	2,300 cron 1 Oct	—	2.5	₹251.75
SAIPARENTSai Parenterals Limited	2,300 cron 1 Oct	—	4.7	₹523.65
SYNCOMFSyncom Formulations (India) Limited	2,300 cron 1 Oct	—	5.4	₹23.95
FREDUNFredun Pharmaceuticals Limited	2,200 cron 1 Oct	—	—	₹1,355.20
WINDLASWindlas Biotech Limited	2,200 cron 1 Oct	—	—	₹1,082.40
PANACEABIOPanacea Biotec Limited	2,200 cron 1 Oct	—	2.6	₹359.05
HESTERBIOHester Biosciences Limited	1,800 cron 1 Oct	—	4.9	₹2,126.80
NGLFINENGL Fine-Chem Limited	1,800 cron 1 Oct	—	5.5	₹2,924.00
AHCLAnlon Healthcare Limited	1,700 cron 1 Oct	—	6.8	₹32.85
FERMENTAFermenta Biotech Limited	1,600 cron 1 Oct	—	—	₹553.25
JAGSNPHARMJagsonpal Pharmaceuticals Limited	1,500 cron 1 Oct	—	5.5	₹231.75
AMRUTANJANAmrutanjan Health Care Limited	1,500 cron 1 Oct	—	4.0	₹513.20
KOPRANKopran Limited	1,400 cron 1 Oct	—	2.6	₹282.05
BPLPHARMABharat Parenterals Limited	1,200 cron 1 Oct	—	—	₹1,720.40
LINCOLNLincoln Pharmaceuticals Limited	1,200 cron 1 Oct	—	1.5	₹582.05
BAJAJHCAREBajaj Healthcare Limited	1,100 cron 1 Oct	—	2.0	₹322.95
SIGACHISigachi Industries Limited	1,100 cron 1 Oct	—	2.0	₹28.35
THEMISMEDThemis Medicare Limited	1,000 cron 1 Oct	—	2.6	₹113.20
SGRLShree Ganesh Remedies Limited	890 cron 1 Oct	—	—	₹694.25
ANUHPHRAnuh Pharma Limited	860 cron 1 Oct	—	2.4	₹85.85
ZIMLABZim Laboratories Limited	740 cron 1 Oct	—	2.5	₹137.00
WANBURYWanbury Limited	690 cron 1 Oct	—	4.8	₹198.00
ALBERTDAVDAlbert David Limited	490 cron 1 Oct	—	1.3	₹856.70
MEDICAMEQMedicamen Biotech Limited	470 cron 17 Sept	—	1.7	₹346.30
HALEOSLABSHALEOS LABS LIMITED	450 cron 1 Oct	—	2.0	₹1,490.00
JENBURPHJenburkt Pharmaceuticals Limited	400 cron 1 Oct	—	—	₹915.25
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	290 cron 1 Oct	—	2.0	₹103.85
NECLIFENectar Lifesciences Limited	200 cron 1 Oct	—	0.34	₹10.25
MEDICOMedico Remedies Limited	180 cron 1 Oct	—	2.4	₹21.85
BALPHARMABal Pharma Limited	170 cron 1 Oct	—	2.0	₹105.75
BROOKSBrooks Laboratories Limited	160 cron 1 Oct	—	1.3	₹54.80
KREBSBIOKrebs Biochemicals and Industries Limited	150 cron 1 Oct	—	—	₹68.05
PARNAXLABParnax Lab Limited	130 cron 1 Oct	—	—	₹113.15
ALPAAlpa Laboratories Limited	120 cron 1 Oct	—	0.67	₹59.25
MAKERSLMakers Laboratories Limited	110 cron 1 Oct	—	—	₹183.50
SUNLOCSunil Healthcare Limited	72 cron 1 Oct	—	—	₹70.10
VINEETLABVineet Laboratories Limited	69 cron 1 Oct	—	1.5	₹35.90
BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited	48 cron 1 Oct	—	2.2	₹29.30
MANGALAMMangalam Drugs And Organics Limited	46 cron 1 Oct	—	0.45	₹29.15
MEDICAPQMedi Caps Limited	31 cron 17 Sept	—	—	₹24.80
ORTINGLOBEORTIN GLOBAL LIMITED	12 cron 1 Oct	—	9.5	₹14.50
AMANTAAmanta Healthcare Limited	—	—	—	—
AMBALALSAAmbalal Sarabhai Enterprises Limited	—	—	—	—
BAFNAPHBafna Pharmaceuticals Limited	—	—	—	—
BLISSGVSBliss GVS Pharma Limited	—	—	—	—
KILITCHKilitch Drugs (India) Limited	—	—	—	—
LASALasa Supergenerics Limited	—	—	—	—
LYKALABSLyka Labs Limited	—	—	—	—
NATCAPSUQNatural Capsules Limited	—	—	—	—
VALIANTLABValiant Laboratories Limited	—	—	—	—
VIVIMEDLABVivimed Labs Limited	—	—	—	—

Shareholding

quarter to 30 Jun · none pledged · NSE filings

Promoters hold 26.6%, foreign portfolio investors 20.7%, mutual funds 13.2% and insurance companies 15.2%, as filed for the quarter to 30 Jun.

26.6%20.7%13.2%15.2%12.6%

By category, last 5 quarterspercent of shares · beneath each figure, the change in percentage points against the previous quarter on file

Shareholding of DRREDDY by category over the last 5 quarters with the change against the previous quarter
Category	30 Jun	31 Mar	31 Dec	30 Sept	30 Jun
Promoters	26.64▲ +0.01 pp	26.63▼ −0.01 pp	26.640.00 pp	26.640.00 pp	26.64
Foreign portfolio investors	20.67▼ −0.47 pp	21.14▼ −1.20 pp	22.34▼ −2.35 pp	24.69▼ −0.64 pp	25.33
Mutual funds	13.16▼ −0.03 pp	13.19▼ −0.68 pp	13.87▲ +0.56 pp	13.31▼ −0.30 pp	13.61
Insurance companies	15.24▲ +0.60 pp	14.64▲ +0.59 pp	14.05▲ +2.14 pp	11.91▲ +1.33 pp	10.58
Banks and financial institutions	3.35▲ +0.46 pp	2.89▲ +0.37 pp	2.52▼ −0.25 pp	2.77▲ +0.23 pp	2.54
Individual investors	8.33▼ −0.16 pp	8.49▼ −0.06 pp	8.55▲ +0.08 pp	8.47▼ −0.51 pp	8.98
Bodies corporate	0.35▲ +0.01 pp	0.34▲ +0.03 pp	0.31▼ −0.05 pp	0.36▲ +0.01 pp	0.35
Other foreign holders	11.43▼ −0.52 pp	11.95▲ +1.07 pp	10.88▲ +0.04 pp	10.84▼ −0.21 pp	11.05
Others	0.83▲ +0.10 pp	0.73▼ −0.11 pp	0.84▼ −0.17 pp	1.01▲ +0.09 pp	0.92

Corporate actions

next results meeting 23 Oct · NSE and BSE records

Nothing upcoming on record; the board meets for results on 23 Oct 2026.

Actionsex-dates · upcoming first, then the last eight · dividends in rupees a share, bonus and split as ratios

Corporate actions of DRREDDY, upcoming first, then the most recent
Ex-date	Action	Amount or ratio	Record date	Source
recent
10 Jul 2026	dividend	₹8.00	10 Jul 2026	BSE
10 Jul 2025	dividend	₹8.00	10 Jul 2025	BSE
28 Oct 2024	split	5→1	28 Oct 2024	BSE
16 Jul 2024	dividend	₹40.00	—	BSE

Calendaras notified to the exchange

Next results: 23 Oct 2026Financial Results To consider and approve the financial results for the period ended September 30, 2026
Dividends in 365 days: ₹16.00a share · ex-dates inside the year
Last dividend: ₹8.00ex-date 10 Jul 2026

Price history

272 sessions on record · to 1 Oct · NSE end of day

DRREDDY is +4.3% over 20 sessions against Nifty's −6.2%, 15% below its 52-week high, realised volatility 22% annualised.

Returns against Nifty 50longest window first · Nifty 50 over the same sessions

Returns of the stock and Nifty 50 over six windows, longest first
Window	From ₹	DRREDDY %	Nifty 50 %	Difference pp
250 sessionssince 26 Sept	₹1,253.06	▼ −3.7%	▼ −9.1%	+5.3
120 sessionssince 9 Apr	₹1,211.90	▼ −0.47%	▼ −5.7%	+5.2
60 sessionssince 8 Jul	₹1,349.07	▼ −11%	▼ −6.1%	−4.5
20 sessionssince 2 Sept	₹1,156.47	▲ +4.3%	▼ −6.2%	+11
5 sessionssince 24 Sept	₹1,200.44	▲ +0.48%	▼ −2.8%	+3.3
1 sessionsince 30 Sept	₹1,232.96	▼ −2.2%	▼ −0.88%	−1.3

Averages of the closeclose against each average

5-session average: ₹1,222.62close −1.3% from it
20-session average: ₹1,181.69close +2.1% from it
50-session average: ₹1,176.25close +2.5% from it
200-session average: ₹1,247.13close −3.3% from it

Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average

Average true range, 14: ₹292.4% of the close
Average day's range, 20: ₹242.0% of the close
Volume against 20 sessions: 1.42×26 L vs 19 L average

Volatility and co-movement with Nifty 50annualised from daily log returns · counts share one denominator per cell

Realised volatility, 20: 22%≈ ±1.4% a session · moved more than that on 7 of 20
Realised volatility, 60: 24%≈ ±1.5% a session · moved more than that on 13 of 60
Realised volatility, 250: 24%≈ ±1.5% a session · moved more than that on 54 of 250
Beta to Nifty, 60: 0.29moved with Nifty on 36 of 60 sessions
Beta to Nifty, 250: 0.48moved with Nifty on 150 of 250 sessions

Up and down sessionscloses above and below the previous close

Last 20 sessions: 10 up · 10 downof 20
Last 60 sessions: 25 up · 35 downof 60
Last 250 sessions: 119 up · 131 downof 250
Best session, 250: ▲ +9.4%23 Apr
Worst session, 250: ▼ −5.9%9 Jul

Dr. Reddy's Laboratories Limited is in 18 NSE indices

all 18 indices

16 bulletins on DRREDDY

latest 29 Sept 2026

Beats in the coverage

Often mentioned with

September 2026

29 Sept Nifty 50 declines as bond yields rise and risks escalateThe Nifty 50 closed at 22,780.25, down 1.56%, as 10-year G-Sec yields rose to 7.17%. The index remains below its 50-day SMA, indicating weak momentum amid geopolitical risks and potential RBI rate hikes.High 25 Sept Dr. Reddy's faces fraud probe after Q1 earnings dropDr. Reddy's Laboratories is being investigated for possible securities fraud after reporting Q1 EPS of $0.06, impacted by a ₹2.4 billion provision for semaglutide batch issues, leading to a 9.4% drop in stock price.High 21 Sept Sensex, Nifty open lower amid crude oil price riseDomestic equity benchmarks opened lower with Sensex down 239.95 points to 76,515.10 and Nifty down 91.45 points to 23,904.80. The Nifty Oil & Gas sector was the worst performer, declining nearly 1% amid rising crude oil prices and geopolitical tensions in West Asia.Medium 20 Sept Sensex, Nifty open lower amid geopolitical tensionsSensex opened at 76,515.10, down 239.95 points, while Nifty started at 23,904.80, slipping 91.45 points. The decline is attributed to rising crude oil prices and geopolitical tensions in West Asia, impacting sectors like Oil & Gas and Pharma.Medium 17 Sept Dr Reddy's Q1FY27 results show revenue decline and margin pressuresDr Reddy's Laboratories reported a 5.6% revenue decline to ₹8,071 crore in Q1FY27, with net profit at ₹443 crore. The EBITDA margin fell to 12.5%, impacted by a ₹240 crore provision for rejected semaglutide batches, indicating ongoing operational challenges.Medium

July 2026

24 Jul Sensex, Nifty open lower on crude oil price riseSensex opened at 76,515.10, down 239.95 points, while Nifty started at 23,904.80, slipping 91.45 points. Rising crude oil prices and geopolitical tensions in West Asia are impacting market sentiment, particularly in the Oil & Gas sector.Medium 23 Jul US House approves $95 billion Iran war funding; Dr Reddy’s declinesThe US House approved a $95 billion funding plan for the Iran war, facing bipartisan opposition. Dr Reddy’s Laboratories shares fell 7% after weaker quarterly results, while the US may soon act on forced labor investigations involving 60 trading partners, including India.Medium 23 Jul Sensex, Nifty open lower amid crude oil price riseDomestic equity benchmarks opened lower on 23 July, with Sensex at 76,515.10, down 239.95 points. Nifty fell to 23,904.80, slipping 91.45 points amid rising crude oil prices and geopolitical tensions in West Asia.Medium 10 Jul Dr Reddy's shares fall on semaglutide supply disruptionDr Reddy's Laboratories shares fell 3% to ₹1,230 due to a supply disruption of its generic semaglutide, raising concerns over earnings risks and potential delays in commercialization.Medium

June 2026

25 Jun Sensex and Nifty rise amid cooling oil pricesOn 24 June 2026, Sensex rose 212.62 points to 76,413.30 and Nifty gained 30 points to 23,854.10, driven by cooling oil prices and positive US-Iran peace talks. Broader markets underperformed, with midcaps and smallcaps declining over 0.60%.Medium

May 2026

13 May Dr Reddy's Q4 profit falls 86% YoY to ₹221 croreDr. Reddy's Laboratories reported a consolidated net profit of ₹221 crore in Q4, down 86% YoY from ₹1,587 crore. Revenue also fell 12% to ₹7,516 crore, reflecting challenges in key markets, particularly North America.High

February 2026

19 Feb Dr. Reddy’s enters hormone replacement therapy marketDr. Reddy’s Laboratories acquired trademarks for Progynova and Cyclo-Progynova from Mercury Pharma, enhancing its gynaecology portfolio. Progynova recorded sales of ₹100 crore in 2025, marking a strategic entry into the hormone replacement therapy market.Medium 19 Feb Dr. Reddy’s enters hormone replacement therapy marketDr. Reddy’s Laboratories acquired trademarks for Progynova and Cyclo-Progynova from Mercury Pharma, enhancing its gynaecology portfolio. Progynova, with sales of ₹100 cr, positions the company strategically in the hormone replacement therapy market.Medium

December 2025

13 Dec Delhi High Court allows Dr. Reddy's to export SemaglutideThe Delhi High Court denied Novo Nordisk's plea to stay an order allowing Dr. Reddy's to manufacture and export Semaglutide to non-patent territories. This ruling may strengthen Dr. Reddy's competitive position in these markets.Medium 12 Dec Delhi High Court allows Dr Reddy’s to export Ozempic-like drugThe Delhi High Court upheld an order allowing Dr Reddy’s Laboratories to export a drug similar to Ozempic, rejecting Novo Nordisk's patent infringement claims. This ruling could enhance Dr Reddy's market position in regions without patent protection.Medium 4 Dec Delhi High Court allows Dr. Reddy's to manufacture semaglutideMedium

About Dr. Reddy's Laboratories Limited

exchange masters as of 18 Sept 2026 · classification by BSE

Company: Dr. Reddy's Laboratories Limited
Exchange: NSE · BSE 500124, group A
Listed on NSE: 30 May 2003
Classification: Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Index: BSE 100
Face value: ₹1 a share
ISIN: INE089A01031
Sessions on record: 272
Price source: NSE UDiFF bhavcopy · end of day · delayed
Filings: NSE and BSE public disclosures · results, shareholding and corporate actions as filed
Computed: 1 Oct, 10:09 pm IST
Bulletins: 16 · written by the desk · not a recommendation

OI Charts is not a SEBI-registered investment adviser or research analyst. Prices, open interest, filings and the desk read are exchange data and arithmetic on it, not a basis for any investment decision.